Status:
UNKNOWN
COVID-19 Antibody Responses In Cystic Fibrosis
Lead Sponsor:
Queen's University, Belfast
Collaborating Sponsors:
Cystic Fibrosis Foundation
Conditions:
Covid19
Cystic Fibrosis
Eligibility:
All Genders
Brief Summary
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in...
Detailed Description
This is a prospective, longitudinal cohort study in people with Cystic Fibrosis (pwCF) that involves repeated serial sampling of participants. This study design was chosen to provide comprehensive inf...
Eligibility Criteria
Inclusion
- • Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity
Exclusion
- Refusal to give informed consent
- Contraindication to venepuncture.
- Participants already enrolled in a clinical trial are eligible for enrollment in this study. Inclusion in CAR-CF should not preclude enrollment in other observational clinical trial studies or clinical trials of an investigational medicinal product (CTIMP).
Key Trial Info
Start Date :
November 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04863573
Start Date
November 19 2021
End Date
May 1 2024
Last Update
February 1 2022
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Southampton Nhs Foundation Trust
Southampton, Engladn, United Kingdom, SO16 6YD
2
University Hospitals Birmingham Nhs Foundation Trust
Birmingham, England, United Kingdom, B15 2GW
3
Birmingham Women'S and Children'S Nhs Foundation Trust
Birmingham, England, United Kingdom, B4 6NH
4
Leeds Teaching Hospitals Nhs Trust
Leeds, England, United Kingdom, LS9 7TF